切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2020, Vol. 14 ›› Issue (05) : 312 -316. doi: 10.3877/cma.j.issn.1674-0807.2020.05.010

所属专题: 文献

综述

乳腺组织定位标记夹在乳腺外科中的应用
王昭蕊1, 裴静1,()   
  1. 1. 230032 合肥,安徽医科大学第一附属医院乳腺外科
  • 收稿日期:2018-10-12 出版日期:2020-10-01
  • 通信作者: 裴静

Application of breast tissue marker clip in breast surgery

Zhaorui Wang1, Jing Pei1()   

  • Received:2018-10-12 Published:2020-10-01
  • Corresponding author: Jing Pei
引用本文:

王昭蕊, 裴静. 乳腺组织定位标记夹在乳腺外科中的应用[J]. 中华乳腺病杂志(电子版), 2020, 14(05): 312-316.

Zhaorui Wang, Jing Pei. Application of breast tissue marker clip in breast surgery[J]. Chinese Journal of Breast Disease(Electronic Edition), 2020, 14(05): 312-316.

乳腺组织定位标记夹是一种可经皮穿刺并在乳腺病灶组织中放置、具有定位标记作用的含金属标志物,主要用于可疑小肿块及不可触及乳腺癌的标记、接受新辅助治疗的乳腺癌的标记、新辅助治疗前阳性淋巴结的标记以及指导随后的定位切除。相对于现阶段最常用的导丝定位技术,乳腺组织定位标记夹的应用是一种创新与补充,特别是对于穿刺活组织检查后影像学检查无法定位的乳腺癌以及新辅助治疗达到pCR或接近pCR的影像学阴性乳腺癌,其成为术前唯一能精确定位原发肿块位置的技术。但是,该技术仍存在放置后移位等问题,其安全性、临床效果以及适应证等有待进一步的深入研究。

图1 超声引导下置入乳腺肿块标记夹
图2 置入乳腺肿块的标记夹在超声下显影
图3 术前导丝定位乳腺肿瘤位置
图4 导丝引导下切除乳腺肿瘤
[1]
Desantis CE, Ma J, Goding AS, et al. Breast cancer statistics, 2017, racial disparity in mortality by state [J]. Ca Cancer J Clin, 2017, 67(6):439-448.
[2]
Yang Z, Zheng R, Zhang S, et al. Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013[J]. Chin J Cancer Res,2017,29(5):385-394.
[3]
Brenner RJ. Percutaneous removal of postbiopsy marking clip in the breast using stereotactic technique[J]. AJR Am J Roentgenol, 2001,176(2):417-419.
[4]
Fisher B. Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer[J]. Cancer,1969,24(6):1286-1289.
[5]
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med, 2002, 347(16):1227-1232.
[6]
Barentsz MW, van den Bosch MA, Veldhuis WB, et al. Radioactive seed localization for non-palpable breast cancer[J]. Br J Surg,2013,100(5):582-588.
[7]
Volders JH, Haloua MH, Krekel NM, et al. Current status of ultrasound-guided surgery in the treatment of breast cancer[J]. World J Clin Oncol,2016,7(1):44-53.
[8]
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997, 16(7):2483-2493.
[9]
郑新宇.乳腺癌保乳手术切缘问题[J].中国实用外科杂志,2011,31(10):928-931.
[10]
Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence[J]. J Clin Oncol,2000,18(8):1668-1675.
[11]
Patel J, Jenkins S. A technique for marking oncological breast tissue specimens[J].Ann Med Surg (Lond), 2016,7:7-8.
[12]
Gray RJ, Pockaj BA, Garvey E, et al. Intraoperative margin management in breast-conserving surgery: a systematic review of the literature[J]. Ann Surg Oncol, 2018,25(1):18-27.
[13]
Rahusen FD, Taets van Amerongen AH, van Diest PJ, et al. Ultrasound-guided lumpectomy of nonpalpable breast cancers: A feasibility study looking at the accuracy of obtained margins[J].J Surg Oncol,1999, 72(2):72-76.
[14]
Reedijk M, Hodgson N, Gohla G, et al. A prospective study of tumor and technical factors associated with positive margins in breast-conservation therapy for nonpalpable malignancy[J].Am J Surg, 2012, 204(3):263-268.

URL    
[15]
Nurko J, Mancino AT, Whitacre E, et al. Surgical benefits conveyed by biopsy site marking system using ultrasound localization[J]. Am J Surg, 2005, 190(4):618-622.
[16]
Corsi F, Sorrentino L, Sartani A, et al. Localization of nonpalpable breast lesions with sonographically visible clip: optimizing tailored resection and clear margins[J]. Am J Surg,2015,209(6):950-958.
[17]
Baltzer PA, Benndorf M, Dietzel M, et al. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study[J]. AJR Am J Roentgenol,2010,194(6):1658-1663.
[18]
Mahoney MC, Newell MS. Breast intervention: how I do it[J]. Radiology, 2013, 268(1):12-24.

URL    
[19]
鲁伦博,孔德兴,谢叻,等. 磁共振成像引导下乳腺病灶定位与活组织检查[J/CD]. 中华乳腺病杂志(电子版), 2018, 12(2):110-112.
[20]
Hong MJ, Cha JH, Kim HH, et al. Second-look ultrasonography for MRI-detected suspicious breast lesions in patients with breast cancer[J]. Ultrasonography,2015,34(2):125-132.
[21]
Spick C, Baltzer PA. Diagnostic utility of second-look US for breast lesions identified at MR imaging: systematic review and meta-analysis[J]. Radiology, 2014, 273(2):401-409.

URL    
[22]
Thomassin-Naggara I, Lalonde L, David J, et al. A plea for the biopsy marker: how, why and why not clipping after breast biopsy?[J]. Breast Cancer Res Treat, 2012,132(3):881-893.
[23]
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet,2014,384(9938):164-172.

URL    
[24]
Dash N,Chafin SH,Johnson RR.Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer[J]. Am J Roentgenol,1999,173(4):911-917.
[25]
Oh JL, Nguyen G, Whitman GJ, et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy[J]. Cancer, 2007,110(11):2420-2427.
[26]
Kumar A, Puri R, Gadgil PV, et al. Sentinel lymph node biopsy in primary breast cancer: window to management of the axilla[J]. World J Surg,2012,36(7):1453-1459.

URL    
[27]
Fu JF,Chen HL,Yang J,et al.Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis[J].PLoS One,2014,9(9):e105316.
[28]
Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J]. J Clin Oncol,2005,23(12):2694-2702.
[29]
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review[J]. JAMA Oncol,2017,3(4):549-555.
[30]
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA,2013,310(14):1455-1461.
[31]
Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance)[J]. Ann Surg,2016,263(4):802-807.
[32]
《乳腺癌新辅助化疗后的病理诊断专家共识》编写组. 乳腺癌新辅助化疗后的病理诊断专家共识[J]. 中华病理学杂志,2015, 44(4): 232-236.
[33]
Barentsz MW, Verkooijen HM, Pijnappel RM, et al. Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed: An ideal prospective development study[J]. Int J Surg, 2015, 14:1-6.
[34]
van Nijnatten TJA, Simons JM, Smidt ML, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a dutch prospective multicenter validation study[J]. Clin Breast Cancer,2017,17(5):399-402.
[35]
Rosen EL, Vo TT. Metallic clip deployment during stereotactic breast biopsy: retrospective analysis[J]. Radiology, 2001, 218(2):510-516.
[36]
Esserman LE, Cura MA, Dacosta D. Recognizing pitfalls in early and late migration of clip markers after imaging-guided directional vacuum-assisted biopsy[J]. Radiographics, 2004, 24(1):147-156.
[37]
Rüland AM, Hagemann F, Reinisch M, et al. Using a new marker clip system in breast cancer: Tumark Vision® clip-feasibility testing in everyday clinical practice[J]. Breast Care (Basel),2018,13(2):116-120.
[38]
Sakamoto N, Ogawa Y, Tsunoda Y, et al. Evaluation of the sonographic visibility and sonographic appearance of the breast biopsy marker (UltraClip®) placed in phantoms and patients[J]. Breast Cancer, 2017, 24(4):585-592.
[39]
Carmon M, Olsha O, Gekhtman D, et al. Detectability of hygroscopic clips used in breast cancer surgery[J]. J Ultrasound Med,2017,36(2):401-408.
[40]
中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,27(9):695-760.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(08): 844-848.
[2] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J]. 中华医学超声杂志(电子版), 2023, 20(06): 631-635.
[3] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[4] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[5] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[6] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[7] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[8] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[9] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[10] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[11] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[12] 冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[13] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[14] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要